BioVentrix
PrivateLast Round
Debt
Apr 24, 2026
Total Funding Raised
$56.57M
Company Overview
BioVentrix, Inc. is a clinical-stage medical device company focused on developing less invasive therapies for patients with congestive heart failure. The company's primary technology, the Revivent TC System, is designed to treat a dilated left ventricle, a common cause of heart failure, by using myocardial micro-anchor implants to reconstruct the ventricle and improve cardiac function. This procedure, known as Less Invasive Ventricular Enhancement (LIVE), offers an alternative to more invasive surgical options. The company is privately held and venture-backed, actively pursuing Premarket Approval (PMA) from the U.S. Food and Drug Administration (FDA) to commercialize its technology.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Clinical Trials
Business Model
B2B
Customer Profile
Hardware Sales
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
BioVentrix Comps
Public and private peers based on sector, stage, and business model.
BioVentrix Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Debt | Apr 24, 2026 | ||||
| IPO Announced | Feb 12, 2026 | ||||
| VC Round | Oct 10, 2024 | ||||
| Series A | Apr 13, 2023 | ||||
| VC Round | Sep 25, 2020 | ||||
VC Round | Mar 29, 2019 |
Key People
Founding team and executive leadership
BioVentrix Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Richmond Brothers | Series A |
| Taglich Brothers | Series A |
| Andera Partners | Series A |
| The Benchmark Company | ipo |
| Squarepoint Ventures | Series A |
| Cormorant Asset Management | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 24, 2026
$705K raised in Seed Round funding.
- Feb 12, 2026
Raised $17M in an IPO round.
BioVentrix Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about BioVentrix's valuation, stock price, and market status.
